https://www.rp2s.fr/wp-content/uploads/2024_HepB_18mars.pdf 2024 France guideline Unknown Site of New Tumor Event Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed Unknown if Medication Taken Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown 1p/19q Codeletion Status Unknown Not Known if NF1 Mutation Analysis Was Performed Tumor Reoccurrence Unknown After Initial Treatment Unknown History of Kawasaki Disease Unknown Daily Fluid Intake Unknown if Subsequent Known Primary Melanoma(s) Found During the Follow-Up Not Known if EGFR Amplification Analysis Was Performed Cancer History Unknown Not Known if MGMT Promoter Methylation Testing Was Performed Evidence of Disease Unknown after Completion of Therapy Unknown History of Congenital Heart Disease Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown hepatitis surface antigen Not Known if SDH Complex Mutation Analysis Was Performed Hypertension Unknown Stage Unknown First Course Treatment Completion Measure of Success of Outcome Unknown Unknown History of Alcohol Use Not Known if KRAS Mutation Analysis Was Performed Not Known if PDGFRA Mutation Analysis Was Performed Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor
Event Not Known if Fluorescence In Situ Hybridization Was Performed Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis Unknown History of Gestational Complication Not Known if MET Mutation Analysis Was Performed Not Known if ALK Rearrangement Analysis Was Performed surrogate mother Not Known if 1p/19q Deletion Analysis Was Performed Unknown Daily Salt Intake Unknown History of Non-Cardiac Surgery Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed Not Known if BRAF Mutation Analysis Was Performed Tumor Progression Unknown After Initial Treatment Sex Not Known hepatitis B Performance Status Scale Timing Unknown Unknown if Chief Complaint was Witnessed Not Known if BRAF Rearrangement Analysis Was Performed Not Known if RET Rearrangement Analysis Was Performed Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor
Event History of Medical Treatment Unknown Unknown Age When Started using Smokeless Tobacco after Regular Use Adjuvant Post-operative Pharmaceutical Therapy Administration Unknown Use of Smokeless Tobacco at Time of Diagnosis Unknown Unknown GENC Unknown Tamoxifen Use New Tumor Event After Initial Treatment Unknown Charge Additional Surgery for New Tumor Event Unknown Unknown Oral Contraceptive Use birth, nos Unknown if Chief Complaint Caused by Trauma Unknown when Chief Complaint Present Unknown History of Neonatal Complication Not Known if Additional Molecular Studies Were Performed Device Status Unknown Adjuvant Post-operative Radiation Therapy Administration Unknown parturition Unknown if Patient Has Genetic Syndrome Associated with Congenital Heart Defect Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment
for a New Tumor Event Not Known if PTEN Mutation Analysis Was Performed Unknown Procedure Type for New Tumor Event Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed Adjuvant Post-operative Immunological Therapy Administration Unknown Unknown History of Illicit Drug Use Unknown if Routine Cytogenetics were Completed Unknown Clark Level Immunotherapy Status Unknown hepatitis B surface antigens Unknown Family History Cardiovascular Disease or Cardiovascular Disease Risk Factors Regular Smokeless Tobacco Use for Six Weeks or More Unknown Unknown Transformation Additional Surgery for New Loco-Regional Tumor Event Unknown Unknown History of Rheumatic Fever Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection Chemotherapy Status Unknown Unknown Use of Menopausal Hormone Therapy Chemical/Occupational Exposure Type Unknown Unknown Number of Full Term Pregnancies Unknown if Another form of Birth Control was Used Not Known if IDH Family Mutation Analysis Was Performed Chemical/Occupational Exposure History Unknown Not Known if Lymph Node Dissection Was Performed Unknown Molecular Analysis Not Known if EGFR Mutation Analysis Was Performed Molecular Abnormalities Unknown Unknown if Caffeine Consumption is Routine Gestational Carriers Not Known if NRAS Mutation Analysis Was Performed patient care management Not Known if ROS1 Rearrangement Analysis Was Performed Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor
Event Unknown History of Myopathy Unknown Release Mechanism of Action Unknown Daily Caloric Intake Not Known if KIT Mutation Analysis Was Performed Tumor Location Unknown type b viral hepatitis Adjuvant Post-operative Chemotherapy Administration Unknown Documentation Unknown Unknown if New Disease is Multifocal Additional Surgery for New Metastatic Tumor Event Unknown Unknown Dosage Form Category Physician Diagnosed Diabetes Unknown Hepatitis B Infection Birth Time Unknown Route of Administration Follow-Up Form Completion Outcome Measure of Success Unknown Paraneoplastic Syndrome Status is Unknown Tumor Laterality Unknown Not Known if Additional Immunohistochemistry Was Performed Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event Intercurrent Illness is Unknown at Onset of Chief Complaint Not Known if TP53 Mutation Analysis Was Performed Unknown History of Other Muscular Dystrophy or Glycogen Storage Disorder Not Known if ERBB2 Mutation Analysis Was Performed Unknown if Patient was Previously Evaluated for Current Chief Complaint Birth Month Not Known if ATRX Mutation Analysis Was Performed Interferon Gamma Treatment Administration 90 Days Prior to Specimen Resection Unknown
--- https://www.rp2s.fr/wp-content/uploads/2017_HepB.pdf 2017 false false false France French guideline surrogate mother Hepatitis patient care management viral hepatitis type b viral hepatitis birth, nos hepatitis B Gestational Carriers constitution and bylaws
Currated CISMeF NLP mapping